RS20080533A - Triazolopyrazine derivatives useful as anticancer agents - Google Patents

Triazolopyrazine derivatives useful as anticancer agents

Info

Publication number
RS20080533A
RS20080533A RSP-2008/0533A RSP20080533A RS20080533A RS 20080533 A RS20080533 A RS 20080533A RS P20080533 A RSP20080533 A RS P20080533A RS 20080533 A RS20080533 A RS 20080533A
Authority
RS
Serbia
Prior art keywords
anticancer agents
derivatives useful
compounds
formula
triazolopyrazine derivatives
Prior art date
Application number
RSP-2008/0533A
Other languages
English (en)
Inventor
Robert Steven Kania
Mitchell David Nambu
Hengmiao Chen
Jingroung Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Thi Quy Le Phuong
Original Assignee
Pfizer Products Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc., filed Critical Pfizer Products Inc.,
Publication of RS20080533A publication Critical patent/RS20080533A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Pronalazak se odnosi na jedinjenja formule (I) ili njihovih farmaceutski prihvatljivih soli, pri čemu su R1, R2 , R3 i R4 kako je ovde definisano. Pronalazak se takođe odnosi na farmaceutske kompozicije koje sadrže jedinjenja formule I i na postupke za lečenje hiperproliferativnih poremećaja kod sisara primenom jedinjenja formule (I).
RSP-2008/0533A 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anticancer agents RS20080533A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
RS20080533A true RS20080533A (en) 2009-09-08

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0533A RS20080533A (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anticancer agents

Country Status (32)

Country Link
US (2) US7732604B2 (sr)
EP (1) EP2018383B1 (sr)
JP (1) JP4377962B2 (sr)
KR (1) KR101099161B1 (sr)
CN (1) CN101443331A (sr)
AP (1) AP2008004674A0 (sr)
AR (1) AR060994A1 (sr)
AT (1) ATE532785T1 (sr)
AU (1) AU2007251283A1 (sr)
BR (1) BRPI0711809A2 (sr)
CA (1) CA2651363C (sr)
CR (1) CR10383A (sr)
EA (1) EA016204B1 (sr)
EC (1) ECSP088871A (sr)
ES (1) ES2376913T3 (sr)
GE (1) GEP20115174B (sr)
GT (1) GT200700039A (sr)
HN (1) HN2007015177A (sr)
IL (1) IL194813A0 (sr)
MA (1) MA30411B1 (sr)
ME (1) MEP36508A (sr)
MX (1) MX2008014399A (sr)
NL (1) NL2000613C2 (sr)
NO (1) NO20085060L (sr)
NZ (1) NZ572361A (sr)
PE (1) PE20080067A1 (sr)
RS (1) RS20080533A (sr)
TN (1) TNSN08445A1 (sr)
TW (1) TWI346115B (sr)
UY (1) UY30334A1 (sr)
WO (1) WO2007132308A1 (sr)
ZA (1) ZA200809020B (sr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20110009421A1 (en) * 2008-02-27 2011-01-13 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
JP5576802B2 (ja) * 2008-02-28 2014-08-20 ノバルティス アーゲー Ｃ−Ｍｅｔチロシンキナーゼ介在疾患の治療用のイミダゾ［１，２−ｂ］ピリダジン誘導体
JP2011515343A (ja) * 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
EP2298731A4 (en) * 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8912330B2 (en) 2008-12-12 2014-12-16 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
DK2361250T3 (da) 2008-12-22 2013-11-04 Merck Patent Gmbh Nye polymorfe former af 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-on-dihydrogenphosphat og fremgangsmåder til fremstilling deraf
JOP20190231A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN102459283B (zh) * 2009-05-28 2014-11-12 沃泰克斯药物股份有限公司 C-met 蛋白激酶的氨基吡唑三唑并噻二唑抑制剂
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
EP2719699B1 (en) 2009-12-31 2015-07-08 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
NZ703111A (en) * 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
EP2710003A1 (en) 2011-05-16 2014-03-26 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
US9815831B2 (en) 2012-03-30 2017-11-14 Rhizen Pharmaceuticals Sa 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
WO2013151913A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
CN105968115B (zh) * 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
CA2923533C (en) * 2013-09-30 2019-08-06 Korea Research Institute Of Chemical Technology Triazolopyrazine derivatives and uses thereof
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
EP3325471A1 (en) * 2015-07-20 2018-05-30 Genzyme Corporation Colony stimulating factor-1 receptor (csf-1r) inhibitors
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
CN109369656B (zh) * 2015-12-31 2021-05-07 上海医药集团股份有限公司 喹啉类化合物硫酸盐的晶型、制备方法、组合物与应用
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
RU2754856C2 (ru) * 2016-06-20 2021-09-08 Новартис Аг Кристаллические формы соединения триазолопиримидина
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
BR112021011547A2 (pt) 2018-12-14 2021-08-31 Beta Pharma, Inc. Compostos substituídos com organofósforos como inibidores de c-met, e seus usos terapêuticos
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
CZ2002936A3 (cs) * 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
MXPA06000091A (es) * 2003-07-02 2006-04-07 Sugen Inc Arilmetiltriazolo e imidazopirazinas como inhibidores de c-met.
US20050070542A1 (en) 2003-09-03 2005-03-31 Hodgetts Kevin J. 5-Aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US9672526B2 (en) 2012-03-13 2017-06-06 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
EP2018383A1 (en) 2009-01-28
PE20080067A1 (es) 2008-03-10
BRPI0711809A2 (pt) 2011-12-06
CA2651363C (en) 2011-07-12
TWI346115B (en) 2011-08-01
AU2007251283A1 (en) 2007-11-22
JP4377962B2 (ja) 2009-12-02
EA200870423A1 (ru) 2009-04-28
CA2651363A1 (en) 2007-11-22
NO20085060L (no) 2008-12-03
CR10383A (es) 2008-11-11
EP2018383B1 (en) 2011-11-09
UY30334A1 (es) 2008-01-02
US20100105656A1 (en) 2010-04-29
KR20090006187A (ko) 2009-01-14
JP2009536636A (ja) 2009-10-15
AP2008004674A0 (en) 2008-12-31
MEP36508A (en) 2011-02-10
ES2376913T3 (es) 2012-03-20
EA016204B1 (ru) 2012-03-30
MX2008014399A (es) 2008-11-27
TW200804384A (en) 2008-01-16
US7732604B2 (en) 2010-06-08
HN2007015177A (es) 2010-06-09
MA30411B1 (fr) 2009-05-04
AR060994A1 (es) 2008-07-30
CN101443331A (zh) 2009-05-27
IL194813A0 (en) 2009-08-03
NL2000613C2 (nl) 2007-11-20
TNSN08445A1 (fr) 2010-04-14
ATE532785T1 (de) 2011-11-15
ZA200809020B (en) 2009-12-30
GT200700039A (es) 2008-06-02
WO2007132308A1 (en) 2007-11-22
NZ572361A (en) 2012-02-24
GEP20115174B (en) 2011-03-10
KR101099161B1 (ko) 2011-12-27
ECSP088871A (es) 2008-12-30
US20070265272A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
WO2007138472A3 (en) Triazolopyridazine derivatives
RS20050469A (en) Pyrrolopyrimidine derivatives
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
TW200612936A (en) Indole derivatives
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
TW200806300A (en) New therapeutic combinations for the treatment of depression
TW200728307A (en) Novel spirochromanone derivatives
TW200626158A (en) Naphthaline derivatives
MY139446A (en) Novel quinoline derivatives
WO2007112000A3 (en) Treatment of pain
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
TW200639159A (en) Treatment of pain
TW200639156A (en) New compounds
TW200734334A (en) Treatment of substance abuse
TW200637817A (en) 5-aminoindole derivatives
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200716547A (en) Piperidin-4-yl-amide derivatives
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
GEP20115216B (en) New phenanthridine derivatives as bradykinin antagonists
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.